Christopher Sayed
Overview
Explore the profile of Christopher Sayed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alhusayen R, Dienes S, Lam M, Alavi A, Alikhan A, Aleshin M, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39725212
Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for...
2.
Jenkins H, Westerkam L, Sayed C
Clin Exp Dermatol
. 2024 Aug;
50(1):181-182.
PMID: 39172541
No abstract available.
3.
Westerkam L, Pearson L, Sayed C
Clin Drug Investig
. 2024 Feb;
44(3):219-222.
PMID: 38372935
No abstract available.
4.
Westerkam L, Sayed C
J Drugs Dermatol
. 2023 Oct;
22(10):1021-1026.
PMID: 37801538
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel formation. Despite being a fairly common disease with...
5.
Garg A, Rawal S, Akilov O, Alavi A, Ardon C, Bechara F, et al.
Br J Dermatol
. 2023 Mar;
188(6):808-810.
PMID: 36891871
No abstract available.
6.
van Straalen K, Tzellos T, Alavi A, Benhadou F, Cuenca-Barrales C, Daxhelet M, et al.
Dermatology
. 2023 Jan;
239(3):362-367.
PMID: 36630943
Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS...
7.
Midgette B, Strunk A, Akilov O, Alavi A, Ardon C, Bechara F, et al.
Br J Dermatol
. 2022 Sep;
187(6):927-935.
PMID: 36056741
Background: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives: To measure associations between treatment...
8.
Shih T, De D, Daveluy S, Hogeling M, Lowes M, Sayed C, et al.
Am J Clin Dermatol
. 2022 Aug;
23(6):749-753.
PMID: 35930133
Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory skin disease that is often recalcitrant to multiple treatments. In determining biologic candidacy for patients with HS, we propose a paradigm shift...
9.
Bonanno M, Lee O, Sayed C
Pediatr Dermatol
. 2022 Jul;
39(5):737-739.
PMID: 35860857
The influence of the nationwide lockdown orders during the COVID-19 pandemic on the transmission of scabies and lice remains unknown. We conducted a cross-sectional study utilizing UNC patient registry i2b2...
10.
Bui H, Sayed C
Pediatr Dermatol
. 2022 Jun;
39(5):689-694.
PMID: 35766518
Background: Hidradenitis suppurativa (HS) often develops in pediatrics, but few interventional studies include pediatric patients. Objectives: This dual analysis of a pediatric HS cohort and typical eligibility criteria in adult...